Skip to content

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

Investing in Our People: Career Development at Scailyte

At Scailyte, our commitment to nurturing talent and fostering professional growth is evident. We believe that investing in our people is not just good for business, but it’s the right thing to do. Our dedication to career development shines through in several ways:

Performance Reviews: All our teammates undergo a performance review at least annually. This process helps Scailyters understand their strengths, discuss how to nurture them with their line manager and identify areas for improvement. This process also supports the alignment of teammates goals with our organizational objectives.

Individual Development Plans: We recognize that each team member is empowered to lead his/her career trajectory in a unique manner. That’s why all teammates have individual development plans in place. These tailored roadmaps support our Scailyters on their journey towards personal and professional growth.

Skills Development Training: We’re dedicated to equipping our team with the skills they need to excel. Through skills development training, we ensure that our teammates are not just keeping pace with industry trends but also leading the way.

Continuous Learning: Our commitment to growth extends to a comprehensive program that encompasses meticulous onboarding, diverse on-the-job training opportunities, active involvement in business decisions, leadership role assignments, peer training, structured mentoring, and coaching relationships. It’s all part of our mission to empower every Scailyte team member for success.

Thank you to our amazing team for making Scailyte a place where talent is nurtured, careers are built, and futures are bright. Stay tuned for more updates on our commitment to career development!

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News